Journal of Clinical Endocrinology & Metabolism, Vol 72, 958-964, Copyright © 1991 by Endocrine Society

ARTICLES

Investigation and characterization of receptors for pituitary adenylate cyclase-activating polypeptide in human brain by radioligand binding and chemical cross-linking

K Suda, DM Smith, MA Ghatei, JK Murphy and SR Bloom
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a novel peptide of hypothalamic origin which increases adenylate cyclase activity in rat anterior pituitary cell cultures. The 38-amino acid peptide shows a close sequence homology to vasoactive intestinal peptide (VIP). Binding sites for PACAP in membranes from postmortem human brain tissue were studied using [125I]PACAP27 as the radioligand. High specific binding sites (amount of specific binding measured at 0.25 nM [125I]PACAP27 in femtomoles per mg protein +/- SEM; n = 4) were present in hypothalamus (344.5 +/- 13.0), brain stem (343.0 +/- 29.3), cerebellum (292.0 +/- 21.1), cortex (259.6 +/- 19.8), and basal ganglia (259.2 +/- 50.3). Specific binding sites in pituitary, although present, were less abundant (35.0 +/- 8.9). Binding of [125I]PACAP27 was reversible and time, pH, and temperature dependent. Despite the homology with VIP, VIP was a poor inhibitor of [125I]PACAP27 binding (IC50, greater than 1 microM) compared with PACAP27 (IC50, 0.5-1.3 nM) and PACAP38 (IC50, 0.2-1.3 nM). Scatchard plots of [125I]PACAP27 binding showed the presence of both high and lower affinity sites. Chemical cross-linking of PACAP-binding sites revealed that [125I]PACAP27 was bound to polypeptide chains of 67,000 and 48,000 mol wt. Thus, we have demonstrated the presence of PACAP-specific receptors in human brain which are not VIP receptors. This opens the possibility of PACAP functioning as a novel neurotransmitter/neuromodulator in human brain.

This article has been cited by other articles:

				D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]

				F. Satoh, S. A. Beak, C. J. Small, M. Falzon, M. A. Ghatei, S. R. Bloom, and D. M. Smith Characterization of Human and Rat Glucagon-Like Peptide-1 Receptors in the Neurointermediate Lobe: Lack of Coupling to Either Stimulation or Inhibition of Adenylyl Cyclase Endocrinology, April 1, 2000; 141(4): 1301 - 1309. [Abstract] [Full Text] [PDF]

				M. L. Scaldaferri, A. Modesti, C. Palumbo, S. Ulisse, A. Fabbri, E. Piccione, G. Frajese, and C. Moretti Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and PACAP-Receptor Type 1 Expression in Rat and Human Placenta Endocrinology, March 1, 2000; 141(3): 1158 - 1167. [Abstract] [Full Text] [PDF]

				M. Hirose, Y. Furukawa, Y. Nagashima, M. Lakhe, and S. Chiba Pituitary Adenylate Cyclase-Activating Polypeptide-27 Causes a Biphasic Chronotropic Effect and Atrial Fibrillation in Autonomically Decentralized, Anesthetized Dogs J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 478 - 487. [Abstract] [Full Text]

				J. R. Pisegna and S. A. Wank Cloning and Characterization of the Signal Transduction of Four Splice Variants of the Human Pituitary Adenylate Cyclase Activating Polypeptide Receptor. EVIDENCE FOR DUAL COUPLING TO ADENYLATE CYCLASE AND PHOSPHOLIPASE C J. Biol. Chem., July 19, 1996; 271(29): 17267 - 17274. [Abstract] [Full Text] [PDF]